-
-
Representing China Resources Pharmaceutical (03320.HK), China Resources Zizhu, China Resources Sanjiu (000999.SZ), and China Resources Double Crane (600062.SH) in multiple asset transactions and product cooperation projects.
-
Providing legal services for a series of technology transactions for XtalPi Technology (02228.HK).
-
Advising GenFleet Pharmaceutical on a license-out transaction for its KRAS G12C Inhibitor (GFH925) with Innovent Biologics, a license-out transaction for a CDK9 small molecule inhibitor with SELLAS Life Sciences Group (NDAQ: SLS), and a collaboration transaction regarding a CXCR4 inhibitor with BioLineRx (NDAQ: BLRX).
-
Representing Yiming Kangda in its license-out transactions with Chia Tai Tianqing and Hualan Bio (002007.SZ).
-
Advising Sinotau Pharmaceutical on multiple international and domestic pipeline cooperation transactions, including projects involving ADCs and radionuclide drugs.
-
Assisting Escugen Bio in securing a license-out agreement for an ADC drug with an overseas partner.
-
Representing CoJourney Bio in executing a technology collaboration transaction.
-
Facilitating financing transactions for companies such as Sironax, Huahui Anjian, GenFleet Pharmaceutical, Nanos Medical, MAB WORKS, and Yiming Kangda.
-
Representing Sequoia China in investments across projects including Gempharmatech, AccuMedical, Shukun Technology, Infervision Technology, and Xihu Bio.
-
Advising IDG Capital on its investments in Caike Bio and Gensciences.
-
Assisting River Head Capital in its investment in Chaoju Eye Care.
- Representing WuXi AppTec in its acquisition of pharmaceutical manufacturing facilities
-
Honors and Awards
- 2024-2025 Recognized in Chambers Greater China Region for Private Equity
- 2022-2025 Recognized in The Legal 500 for Private Equity
- 2024 Recognized in LEGALBAND for Life Sciences
- 2024 Named to China Business Law Journal (CBLJ) The A-List: Rising Stars
- 2023 Named a LEGALBAND Top 20 Lawyer in New Economy
Work Language
- English
- Mandarin
